· **Hypnotics:** e.g. drug finishing in:

 -obarbital (e.g. Phenobarbital)

 -Zdrugs: Zolpidem, Zopiclone

· **Benzodiazepines:** e.g. drug finishing in:

 -azolam (e.g. Midazolam)

 -azepam (e.g Diazepam, Lorazepam)

 -azam (e.g. Clobazam)

· **Drugs which require close and careful monitoring;** e.g. methotrexate

· **Unlicensed medicines**

· **Patients on multiple therapy:** e.g. diabetes, hypertension, asthma

· **Patients that are up to date with their medication monitoring:** e.g. medication review, blood tests, blood pressure

· **Patients with stable, long term medical conditions**

-no recent unplanned hospital admissions in the last 6 months

-no new conditions diagnosed in the last 6 months

· **Controlled drugs** (including Tramadol, Gabapentin, Pregabalin)

· **Patients on stable medication:**

-no change in their medication in at least 6 months

-no anticipated change in their medication for the duration of the batch of eRD

-Stable dosage regimes

**Exclusion criteria**

**Suitability for eRD**

**Identifying patients when repeat prescriptions are requested**

This is an ideal opportunity to identify potential patients suitable for eRD.

The following guidance may be used to highlight possible patients that may be suitable for eRD.

**Electronic Repeat Dispensing (eRD)**